PDL BioPharma Liquidation May Offer 40% Upside For Patient Investors Comfortable With Illiquidity

Retrieved on: 2020-12-04 16:41:15

Tags for this article:

Money

Finance

Intellectual property law

Patent law

Royalty payment

Assertio Therapeutics

Net asset value

Rate of return

PDL BioPharma

NASDAQ COMPOSITE INDEX

Click the tags to see associated articles and topics

PDL BioPharma Liquidation May Offer 40% Upside For Patient Investors Comfortable With Illiquidity. View article details on HISWAI: https://seekingalpha.com/article/4393029-pdl-biopharma-liquidation-may-offer-40-upside-for-patient-investors-comfortable-illiquidity

Excerpt

Pharma company PDL <b>BioPharma</b> (PDLI), with material royalty streams, has been in the process of unlocking the value of its portfolio since December ...

Article found on: seekingalpha.com

View Original Article